Endo Pharmaceuticals issues voluntary recall for two lots of methocarbamol tablets

Endo Pharmaceuticals has announced a voluntary nationwide recall of two lots of methocarbamol (Robaxin) tablets 750 mg to the consumer level. The recall was initiated due to a labeling error that included incorrect daily dosing information.

Endo Pharmaceuticals has announced a voluntary nationwide recall of two lots of methocarbamol (Robaxin) tablets 750 mg to the consumer level. The recall was initiated due to a labeling error that included incorrect daily dosing information. Instead of the correct dosage of "two tablets three times daily," the products in the affected lots list the daily dose as "two to four tablets four times daily." Endo has not received any reports of adverse events related to the recall. However, patients who follow the incorrect directions on the bottle could experience significant drowsiness or dizziness that could put them at risk of falls or an overdose that could lead to seizures, coma, or death. The affected products are packaged in bottles of 100 tablets with package labeling featuring the product name, strength, lot number, expiry date and the National Drug Code number NDC 52244-449-10. The recall includes product lot numbers 216702P1, with a September 2020 expiration date, and 220409P1, with a January 2021 expiration date.